A trial to learn how safe AZD9550 monotherapy and combined with AZD6234 is in people with or without type 2 diabetes who are living with obesity and overweight

Trial Identifier: D8460C00002
Sponsor: AstraZeneca
Start Date: September 2023
Primary Completion Date: January 2027
Study Completion Date: January 2027

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AT Graz, AT, 8036
AT Vienna, AT, 1090
CA, British Columbia Surrey, British Columbia, CA, V3T 4G8
CA, ON Sarnia, ON, CA, N7T 4X3
CA, ON Stouffville, ON, CA, L4A 1H2
CA, ON Toronto, ON, CA, M4G 3E8
CA, Ontario Hamilton, Ontario, CA, L8L 5G8
CA, QC Sherbrooke, QC, CA, J1L 0H8
DE Magdeburg, DE, 39120
DE Neuss, DE, 41460
DE Neu-Ulm, DE, 89231
JP Fukuoka-shi, JP, 812-0025
JP Shinjuku-ku, JP, 160-0004
JP Suita-shi, JP, 565-0853
SE Uppsala, SE, 752 37